Table 1. Prevalence, 95% confidence intervals, and mean fluorescence intensity of IgG responses to PvGAMA-Ecto fragment in vivax malaria patients and healthy individual serum samples.
Patients/healthy from each country | No. of samples | |||||
---|---|---|---|---|---|---|
Positive | Negative | Total (%)a | 95% CIb | MFIc | p valuee | |
Patients | ||||||
Korea | 23 | 27 | 50 (46.0) | 32.9–59.6 | 12139.2 | p < 0.0001 |
Myanmar | 44 | 6 | 50 (88.0) | 76.2–94.4 | 18986.9 | p < 0.0001 |
Thailand | 29 | 8 | 37 (78.4) | 62.8–88.6 | 19039.2 | p < 0.0001 |
China | 17 | 3 | 20 (85.0) | 64.0–94.8 | 25453.1 | p < 0.0001 |
Total | 113 | 44 | 157 (72.0) | 64.5–78.4 | 17642.1 | |
Healthy individuals | ||||||
Korea | 2 | 48 | 50 (96.0) | 86.5–98.9 | 3540.2 |
aSensitivity: percentage of positive in patient samples.
bCI: confidence interval.
cMFI: mean fluorescence intensity.
dSpecificity: percentage of negative in healthy samples.
eDifferences in the total IgG prevalence for each antigen between vivax patients and healthy individuals were calculated by Student’s t-test. A p value of < 0.05 is considered statistically significant.